A Prospective Population Based Cohort of XXXX in the Biologics era - Disease Course and Predictors of Severity.

@entity1 @entity32 @entity66 @entity31 @entity29 @entity30
UNASSIGNED: We have previously found high incidence of @entity29 ( @entity29 ) in Australia. A population-based registry was established to assess disease severity, frequency of complications and prognostic factors. METHOD: Incident cases were prospectively identified over 4 years. Early disease severity was assessed according to need for hospitalization and resective surgery and medication use. RESULTS: We report on the early outcomes (median 18 months, range 12-60 months) for 252 @entity1 comprising 146 with @entity30 ( @entity30 ), 96 with @entity31 ( @entity31 ) and 10 IBDU ( @entity29 undifferentiated). 87% of @entity30 @entity1 had @entity32 at diagnosis, and this reduced to 73% at 5 years (n=38). Immunomodulators (IM) were prescribed in 57% of @entity30 @entity1 , and 19% with @entity31 . A third of all @entity30 @entity1 were hospitalised, the majority (77%) in the first 12 months. Risk factors for hospitalisation included penetrating, perianal and @entity66 (p<0.05). 24% of @entity31 @entity1 were hospitalized, most within the first 12 months. Intestinal resection rates were 13% at 1 year in @entity30 , and 26% at 5 years. Risk factors include penetrating and stricturing disease (p<0.001), and ileal involvement (p<0.05). Colectomy rates in @entity31 were 2% and 13% at 1 and 5 years. High CRP at diagnosis was associated with colectomy. CONCLUSION: A high rate of @entity32 , frequent IM use in @entity30 and a low rate of surgery in both @entity30 and @entity31 were identified. In @entity30 , ileal involvement and complex disease behaviour are associated with a more severe disease course; while in @entity31 a high CRP predicted this outcome.
